Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,570 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolic and Nutritional Complications Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

NCT07024823
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
AZD4248, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

NCT07228403
View directory record Official record
Conditions
Short Bowel Syndrome (SBS)
Interventions
Glepaglutide 10 mg
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Rochester, Minnesota • Omaha, Nebraska • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Withdrawn Not applicable Interventional

Evaluation of the Ketogenic Diet to Improve Post Operative Cognitive Decline in Cardiac Surgery

NCT06480708
View directory record Official record
Conditions
Postoperative Cognitive Dysfunction
Interventions
Ketogenic diet, Control diet
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116
View directory record Official record
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

NCT01464320
View directory record Official record
Conditions
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
Interventions
ABT-614, Placebo Comparator
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Oct 16, 2026, 1:05 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 16, 2026, 1:05 AM EDT
Not listed No phase listed Observational

DKA Optic Ultrasound

NCT02130180
View directory record Official record
Conditions
Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
7 Years to 18 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis and Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Not applicable Interventional

Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria

NCT00493727
View directory record Official record
Conditions
Diabetes, Proteinuria
Interventions
N-acetylcysteine(Mucomyst)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Phase 3 Interventional

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

NCT05299554
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
16 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074
View directory record Official record
Conditions
CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 16, 2026, 1:05 AM EDT
Recruiting Phase 3 Interventional

IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department

NCT05304442
View directory record Official record
Conditions
Anemia, Iron Deficiency, Uterine Bleeding
Interventions
Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric], Ferrous Sulfate 65 mg elemental iron (325 mg tablets)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

NCT01932970
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Alhambra, California • Azusa, California • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 16, 2026, 1:05 AM EDT
Recruiting No phase listed Observational

Rare and Atypical Diabetes Network

NCT05544266
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

NCT05254002
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Empagliflozin Placebo, Finerenone (BAY94-8862 ) 20 mg, Finerenone Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
46
States / cities
Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia

NCT03749746
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension, Hypertension, Obesity, Overweight and Obesity, Pregnancy Complications, Pregnancy Toxemia, Postpartum Preeclampsia
Interventions
Home Blood Pressure Monitoring, Heart Health 4 New Moms, Usual care
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 16, 2026, 1:05 AM EDT
Recruiting Not applicable Interventional

SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease

NCT06480786
View directory record Official record
Conditions
Peripheral Arterial Disease, Painful Diabetic Neuropathy, Diabetes Mellitus, Type 2, Chronic Pain, Spinal Cord Stimulation, Chronic Pain Syndrome, Limb Pain
Interventions
Spinal cord stimulation, Sham stimulation
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

NCT00704483
View directory record Official record
Conditions
Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Interventions
SBR759, Sevelamer HCl
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • La Mesa, California • Whittier, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 16, 2026, 1:05 AM EDT
Recruiting Phase 2 Interventional

Sleep, Diabetic Retinopathy and Melatonin

NCT04547439
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
Melatonin, Placebo
Drug · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Not applicable Interventional Results available

The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery

NCT01831154
View directory record Official record
Conditions
Diabetes, Hyperglycemia, Surgical Site Infection
Interventions
Tight Glycemic, Conventional Glycemic, Standard Glycemic
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 16, 2026, 1:05 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

NAFLD in Adolescents and Young Adults With PCOS

NCT02506946
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
14 Years to 25 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Eating for Reproductive Health (HERHealth)

NCT01509066
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Infertility, Obesity, Overweight
Interventions
Diet
Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lifestyle Intervention in Preparation for Pregnancy (LIPP)

NCT03146156
View directory record Official record
Conditions
Obesity, Lifestyle-related Condition, Macrosomia, Fetal
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Recruiting Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

NCT07536269
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Crinecerfont
Drug
Lead sponsor
Neurocrine Switzerland GmbH
Industry
Eligibility
3 Months to 47 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

NCT01989754
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Albuminuria
Interventions
Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
5,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 16, 2026, 1:05 AM EDT